Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y.

Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12.

PMID:
24728578
[PubMed - in process]
2.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19.

PMID:
24656685
[PubMed - indexed for MEDLINE]
Free Article
3.

[II.Late recurrence and resistance 2. Overcoming a trial for acquired resistance against hormone therapy for breast cancer].

Aogi K.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2510-3. Japanese. No abstract available.

PMID:
24422238
[PubMed - indexed for MEDLINE]
4.

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).

Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H.

Int J Clin Oncol. 2014 Jan 7. [Epub ahead of print]

PMID:
24395447
[PubMed - as supplied by publisher]
5.

Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306.

Mukai H, Watanabe T, Mitsumori M, Tsuda H, Nakamura S, Masuda N, Yamamoto N, Shibata T, Sato A, Iwata H, Aogi K.

Oncology. 2013;85(6):336-41. doi: 10.1159/000355196. Epub 2013 Nov 12.

PMID:
24247597
[PubMed - indexed for MEDLINE]
6.

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M.

Breast Cancer Res Treat. 2013 Nov;142(1):69-80.

PMID:
24122389
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Association of positive EBAG9 immunoreactivity with unfavorable prognosis in breast cancer patients treated with tamoxifen.

Ijichi N, Shigekawa T, Ikeda K, Miyazaki T, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Clin Breast Cancer. 2013 Dec;13(6):465-70. doi: 10.1016/j.clbc.2013.08.015. Epub 2013 Oct 8.

PMID:
24119785
[PubMed - in process]
8.

[Clinical experience with gemcitabine treatment for metastatic breast cancer].

Watanabe M, Hara F, Kiyoto S, Takahashi M, Takabatake D, Takashima S, Aogi K, Ohsumi S.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1355-9. Japanese.

PMID:
24105058
[PubMed - indexed for MEDLINE]
9.

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M.

Int J Clin Oncol. 2013 Oct 8. [Epub ahead of print]

PMID:
24101215
[PubMed - as supplied by publisher]
10.

Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study.

Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M.

Breast Cancer Res Treat. 2013 Sep;141(2):269-75. doi: 10.1007/s10549-013-2687-7. Epub 2013 Sep 13.

PMID:
24026860
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.

Aogi K, Rai Y, Ito Y, Masuda N, Watanabe J, Horiguchi J, Tokudome T, Takashima S.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1427-33. doi: 10.1007/s00280-013-2140-y. Epub 2013 Mar 28.

PMID:
23536163
[PubMed - indexed for MEDLINE]
12.

[Genetic counseling and practice of hereditary cancers at Shikoku Cancer Center].

Kaneko K, Ohsumi S, Aogi K, Kubo Y, Hori S, Matsumoto T, Shiroyama Y, Takabatake D, Takahashi M, Kiyoto S, Tadokoro K, Inoue M, Kikuuchi Y, Tanimizu M.

Gan To Kagaku Ryoho. 2013 Feb;40(2):139-42. Japanese.

PMID:
23411949
[PubMed - indexed for MEDLINE]
13.

[Clinical utility of adjuvant TC regimen].

Aogi K.

Nihon Rinsho. 2012 Sep;70 Suppl 7:597-600. Japanese. No abstract available.

PMID:
23350470
[PubMed - indexed for MEDLINE]
14.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23219286
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.

Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, Masuda N, Inoue K, Fukuda H, Iwata H.

Jpn J Clin Oncol. 2012 Oct;42(10):970-3. Epub 2012 Jul 24.

PMID:
22833684
[PubMed - indexed for MEDLINE]
Free Article
16.

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).

Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T.

Int J Clin Oncol. 2013 Aug;18(4):598-606. doi: 10.1007/s10147-012-0437-1. Epub 2012 Jul 26.

PMID:
22833344
[PubMed - indexed for MEDLINE]
17.

Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.

Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R, Shimizu C, Tsuda H, Moriya T, Sonoo H.

Breast Cancer. 2014 Mar;21(2):214-22. doi: 10.1007/s12282-012-0380-z. Epub 2012 Jun 12.

PMID:
22689016
[PubMed - in process]
18.

Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer.

Inaji H, Iwata H, Nakayama T, Yamamoto N, Sato Y, Tokuda Y, Aogi K, Saji S, Watanabe K, Saito T, Yoshida M, Sato N, Saeki T, Takatsuka Y, Kuranami M, Yamashita H, Kikuchi A, Tabei T, Ikeda T, Noguchi S.

Cancer Sci. 2012 Sep;103(9):1708-13. doi: 10.1111/j.1349-7006.2012.02354.x. Epub 2012 Jul 16.

PMID:
22676245
[PubMed - indexed for MEDLINE]
19.

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.

Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y.

Int J Clin Oncol. 2013 Aug;18(4):590-7. doi: 10.1007/s10147-012-0421-9. Epub 2012 May 15.

PMID:
22585426
[PubMed - indexed for MEDLINE]
20.

Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?

Hamamoto Y, Ohsumi S, Aogi K, Shinohara S, Nakajima N, Kataoka M, Takashima S.

Breast Cancer. 2014 Mar;21(2):177-82. doi: 10.1007/s12282-012-0369-7. Epub 2012 May 9.

PMID:
22569681
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk